case_images: PMC9875126_01
case_images: Timeline presenting the main events throughout the patient's treatment. CT, computer tomography; PD, progression of disease.
case_images: fonc-12-960116-g001.jpg
case_images: PMC9875126_01_fonc-12-960116-g001.jpg
case_images: f1
case_images: The first 200 mg pembrolizumab dose was administered 3 weeks after diagnosis ( Figure 1 ).
case_images: Follow-up of liver enzyme levels and daily prednisolone dose in a patient with NSCLC. Blue line: (A) Alanine aminotransferase (IU/L), (B) aspartate transaminase (IU/L), (C) alkaline phosphatase (IU/L), (D) gamma-glutamyl (IU/L) transferase. Gray bars: Daily prednisolone dose (mg).  : Sample drawn for pembrolizumab quantification after pembrolizumab administration.    : Upper boundary of the liver enzymes' normal range.
case_images: fonc-12-960116-g002.jpg
case_images: PMC9875126_01_fonc-12-960116-g002.jpg
case_images: f2
case_images: Nineteen days after administration, the patient presented with elevated levels of alanine aminotransferase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), and gamma-glutamyl (gamma-GT) transferase ( Figure 2 ).
case_images: Observed pembrolizumab levels after a 200 mg per 3 weeks (Q3W) administration.  : Linear pembrolizumab clearance (samples from 19, 40, 42, 49, 53, 60, 70, 74, and 77 days after administration).  : Non-linear pembrolizumab clearance (samples from 82, 88, 89, and 90 days after administration).  : Below the lower limit of detection (samples from 91 and 123 days after administration).
case_images: fonc-12-960116-g003.jpg
case_images: PMC9875126_01_fonc-12-960116-g003.jpg
case_images: f3
case_images: The highest pembrolizumab level of 9.1 microg/mL, as seen in  Figure 3 , was observed in the earliest sample collected (19 days after the 200 mg pembrolizumab administration).